title: Pseudomonas aeruginosa bacteremia in patients with liver cirrhosis: a comparison with bacteremia caused by Enterobacteriaceae.
abstract: BACKGROUND
  This study was performed to detect risk factors for Pseudomonas aeruginosa bacteremia in patients with liver cirrhosis.
  
  
  METHODS
  A retrospective case-control study was designed to identify risk factors for P. aeruginosa bacteremia in cirrhotic patients. The cases were cirrhotic patients with P. aeruginosa bacteremia and the controls were cirrhotic patients with Enterobacteriaceae bacteremia.
  
  
  RESULTS
  Sixty-one cases and the same number of controls were enrolled. In a multivariate analysis, younger age {adjusted odds ratio (aOR) per one year: 0.96, 95% confidence interval: 0.93 - 0.99}, nosocomial acquisition (aOR 3.87, 95% confidence interval: 1.50 - 9.94), preexisting biliary disease (aOR 4.79, 95% confidence interval: 1.92 - 10.47), and recent exposure to immunosuppressive agent (aOR 3.10, 95% confidence interval: 1.23 - 7.82) were associated with P. aeruginosa bacteremia. In the case group the frequency of appropriate initial antibiotic regimens was considerably lower than in the control group: 29.5% vs. 65.6% (P <0.01). However, thirty day mortality did not differ significantly between cases and controls (19.7% vs. 24.6%).
  
  
  CONCLUSIONS
  Nosocomial acquisition, preexisting biliary disease, and recent use of immunosuppressive agents are strong predictive factors for P. aeruginosa bacteremia in cirrhotic patients.
authors.affiliation: Department of Internal Medicine, Seoul National University College of Medicine, 101 Daehak-ro Jongno-gu, 110-744, Seoul, Republic of Korea.
authors.forename: Ji Hwan
authors.initials: JH
authors.lastname: Bang
authors.forename: Younghee
authors.initials: Y
authors.lastname: Jung
authors.forename: Shinhye
authors.initials: S
authors.lastname: Cheon
authors.forename: Chung Jong
authors.initials: CJ
authors.lastname: Kim
authors.forename: Kyung Ho
authors.initials: KH
authors.lastname: Song
authors.forename: Pyeong Gyun
authors.initials: PG
authors.lastname: Choe
authors.forename: Wan Beom
authors.initials: WB
authors.lastname: Park
authors.forename: Eu Suk
authors.initials: ES
authors.lastname: Kim
authors.forename: Sang Won
authors.initials: SW
authors.lastname: Park
authors.forename: Hong Bin
authors.initials: HB
authors.lastname: Kim
authors.forename: Myoung-don
authors.initials: MD
authors.lastname: Oh
authors.forename: Hyo-Suk
authors.initials: HS
authors.lastname: Lee
authors.forename: Nam Joong
authors.initials: NJ
authors.lastname: Kim
mesh_terms: D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D016470:Bacteremia / Q000150:complications / Q000188:drug therapy / Q000382:microbiology*; D016022:Case-Control Studies; D004755:Enterobacteriaceae / Q000302:isolation & purification; D004756:Enterobacteriaceae Infections / Q000150:complications / Q000188:drug therapy / Q000382:microbiology*; D005260:Female; D006801:Humans; D008103:Liver Cirrhosis / Q000188:drug therapy / Q000382:microbiology*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D016017:Odds Ratio; D011552:Pseudomonas Infections / Q000150:complications / Q000188:drug therapy / Q000382:microbiology*; D011550:Pseudomonas aeruginosa; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents